142 results
8-K/A
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
7:18pm
to be presented at the AACR Annual Meeting – safety and efficacy data from the 40mg pharmacokinetic run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen
8-K
EX-99.1
ATOS
Atossa Therapeutics Inc
1 Apr 24
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
4:00pm
at the AACR Annual Meeting – safety and efficacy data from the 40mg pharmacokinetic run-in cohort of the ongoing Phase 2 EVANGELINE (Endoxifen Versus
8-K
EX-99.1
1bp j42cgah
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
8-K
8mdf9rl8o 7xm
28 Jun 23
Atossa Therapeutics Announces $10M Stock Repurchase Program
9:01am
8-K
EX-99.1
p1rnvyx
15 May 23
Atossa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
9:10am
8-K
EX-99.1
ritsd 6il0d26c
7 Nov 22
Atossa Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
EX-99.1
z9d8p7q
8 Aug 22
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
5we3 6d9ktsc0z
6 Jun 22
Regulation FD Disclosure
2:45pm
8-K
EX-99.1
wvvytde874mq
9 May 22
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
4:00pm
8-K
EX-99.1
n3rqw13tfwuh1j xcm
15 Nov 21
Atossa Therapeutics Announces Third Quarter 2021 Financial Results and Provides Corporate Update
9:25am
DEFA14A
w9inyf p694frh80
14 Sep 21
Additional proxy soliciting materials
4:12pm